Newscast – Page 151 – media

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer

The U.S. Food and Drug Administration(FDA) has expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
- Source: Worldpharmanews
- 443
- November 8, 2017
BRAF V600 ECD FDA Zelboraf (vemurafenib)
Increasing rates of chronic conditions putting more moms, babies at risk

Pregnant women today are more likely to have chronic conditions that could cause life-threatening complications than at any other time in the past decade - particularly poor women and those living in rural communities, a new Michigan Medicine study suggests.
- Source: Medicalxpress
- 390
- November 8, 2017
chronic conditions Researches
Merck, Pfizer launch Bavencio for rare skin cancer

Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
- Source: Pharmatimes
- 488
- November 7, 2017
avelumab Company Insight mMCC skin cancer
Moderna Announces New Collaboration with AstraZeneca

Moderna Therapeutics today announced a new license and collaboration with AstraZeneca to co-develop and co-commercialize a messenger RNA (mRNA) therapeutic encoding for Relaxin. The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
- Source: Modernatx
- 465
- November 7, 2017
heart Market Views mRNA
Just two sugary drinks per week may raise type 2 diabetes risk

The World Health Organization (WHO) report that at least 19 million yearly deaths are from cardiometabolic disorders – an umbrella term for cardiovascular disease and conditions such as metabolic syndrome and type 2 diabetes.
- Source: medicalnewstoday
- 590
- November 7, 2017
cardiometabolic diabetes Market Views WHO
Men with low testosterone less likely to have prostate cancer

New research suggests that men with abnormally low levels of testosterone are less likely to develop prostate cancer in their lifetime. The new study was carried out by scientists at the University of Oxford in the United Kingdom, and the findings were presented at the National Cancer Research Institute (NCRI) Cancer Conference, held in Liverpool, U.K.
- Source: medicalnewstoday
- 574
- November 7, 2017
cancer NCRI prostate Researches testosterone
Scientists discover potential treatment to stop glaucoma in its tracks

Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, the world's second-leading cause of blindness.
- Source: Medicalxpress
- 492
- November 7, 2017
glaucoma lipid mediators neurodegenerative disease
Teva looks to sell generics in China through joint venture with Guangzhou Pharma

As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that by reportedly forming a joint venture with local company Guangzhou Pharma
- Source: Fiercepharma
- 526
- November 7, 2017
China generics Teva
New tissue-engineered blood vessel replacements one step closer to human trials

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doesn't contain any living cells at implantation. The vessel, that could be used as an "off the shelf" graft for kidney dialysis patients, performed well in a recent study with nonhuman primates.
- Source: worldpharmanews
- 539
- November 7, 2017
biological blood vessel kidney dialysis Researches
‘Precision Medicine’ may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the world's more diverse populations, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and the Keck School of Medicine of the University of Southern California (USC).
- Source: worldpharmanews
- 551
- November 6, 2017
cancer oncology precision medicine Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.